Literature DB >> 8685632

Parvovirus B19 infection--persistence and genetic variation.

J R Kerr1, M D Curran, J E Moore, P G Murphy.   

Abstract

53 patients with acute B19 infection were studied; symptoms at acute infection were rash and arthralgia (n = 26), rash (n = 7), arthralgia (n = 16), aplastic crisis (n = 3), and intrauterine fetal death (n = 1). These patients were followed for 26-85 months (mean 57 months) and re-assessed for persistent symptoms, anti-B19 antibodies, and B19 DNA. At follow-up, 7 individuals were positive for serum B19 DNA, compared with none of the controls (2-tailed p value = 0.016). All 7 of those persistently infected were women, 3 of whom had symptoms; 1 had a chronic haemolytic anaemia (initial presentation was aplastic crisis); 1 had persistent arthralgia in both knees (initial presentation was bilateral knee arthralgia); and 1 had arthralgia in one knee and chronic fatigue syndrome (initial presentation was bilateral arthralgia in knees and shoulders). For the 7 persistently infected patients, serum from the time of diagnosis of acute B19 infection was available for 4, all of which contained B19 DNA. With single-stranded conformational polymorphism (SSCP) assay of these 11 PCR products, identical SSCP types were demonstrated in 5 of 7 follow-up isolates. In 2 of the 4 cases for which both acute and follow-up PCR product was available, the SSCP type of the follow-up product was different from that of the acute product. Two B19 virus types were demonstrated in one patient (with persistent arthralgia and chronic fatigue syndrome) at follow-up assessment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8685632     DOI: 10.3109/00365549509047066

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Applications of polymerase chain reaction-single stranded conformational polymorphism to microbiology.

Authors:  J R Kerr; M D Curran
Journal:  Clin Mol Pathol       Date:  1996-12

3.  Detection of parvovirus B19 in skin biopsy, serum, and bone marrow of a patient with fever, rash, and polyarthritis followed by pneumonia, pericardial effusion, and hepatitis.

Authors:  S Nikkari; H Lappalainen; R Saario; K Lammintausta; P Kotilainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

4.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  On the trail of a new virus. The Calvert Lecture 1997.

Authors:  J R Kerr
Journal:  Ulster Med J       Date:  1998-06

6.  Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.

Authors:  Ashleigh Manning; Samantha J Willey; Jeanne E Bell; Peter Simmonds
Journal:  J Infect Dis       Date:  2007-03-21       Impact factor: 5.226

7.  Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration.

Authors:  Yedong Yu; Ruijie Bao; Junhao Lyu; Jianyong Wu; Jianghua Chen; Wenhan Peng
Journal:  Infect Drug Resist       Date:  2021-07-27       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.